Alumis reports LUMUS topline, misses overall endpoints
Alumis said LUMUS Phase 2b topline results missed primary and secondary endpoints overall, but showed robust responses in IFNGS-high patients.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.